Other items from the annual meeting of the AUA

A combination of travel and other commitments made it difficult for your sitemaster to complete his summaries of significant information presented at this year’s annual meeting of the American Urological Association (AUA), so here’s the final wrap-up. … READ MORE …

New STAMPEDE data support earlier CHAARTED trial results

So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …

Re-classification rates on repeat biopsy for men on active surveillance in the Hopkins cohort

So there is an interesting new paper on the ramifications of active surveillance in the forthcoming June issue of the Journal of Urology — based on the extensive data now collected by the Johns Hopkins group through their very conservative active surveillance cohort of > 1,200 men accumulated since 1995. … READ MORE …

Optimal brachytherapy pre-treatment for intermediate-risk patients depends on “favorable” or “unfavorable” status

Anthony D’Amico has been advocating breaking up the intermediate-risk category into “favorable” and “unfavorable,” and now offers yet another circumstance where the optimal treatment is different for each of the two groups, this time with brachytherapy. … READ MORE …

Predicting risk for cancer years before the event

There is a lot of media hype about a paper just published in the online journal EBioScience. The paper suggests that it may, perhaps, be able to project risk for diagnosis of cancer (prostate cancer specifically included) as much as 13 years before the actual event. … READ MORE …

Lycopene, selenium, GTCs, and (maybe?) the prevention of prostate cancer — or maybe not

There have really been very few meaningful, randomized, double-blind trials of any forms of supplement in the prevention of prostate cancer … and to date none of the trials that have been done have shown unarguably meaningful, positive results. … READ MORE …

Early data from the ASCENDE-RT trial misleadingly presented

News reports (and apparently a media release) have been suggesting that ‘A prostate cancer treatment using permanently implanted radioactive “seeds” doubles rates of 5-year tumor-free survival compared with conventional high-dose radiotherapy.’ Unfortunately, these reports are somewhat — or perhaps very — misleading. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,284 other followers